{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.7"},{"groupId":"OG001","value":"39.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"138"}],"units":"Participants"}],"description":"Surgery was categorized as breast conserving surgery (\"Partial Mastectomy\") or non-conserving surgery (\"Total Mastectomy\" or \"Modified Radical Mastectomy). Reported below is the percentage of patients receiving \"Partial Mastectomy\". This was calculated by dividing the number of patients receiving \"Partial Mastectomy\" by the total number of patients undergoing surgery multiplied by 100 (to obtain the percentage).","groups":[{"description":"Patients receive Fluorouracil, epirubicin, and cyclophosphamide (FEC) comprising fluorouracil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Beginning 21 days after completion of FEC, patients receive paclitaxel IV once weekly and trastuzumab (Herceptin) IV once weekly for 12 weeks. Within 6 weeks after completion of paclitaxel and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab IV once every 3 weeks for up to 52 weeks. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies","id":"OG000","title":"FEC-75 Then Paclitaxel/Trastuzumab"},{"description":"Patients receive paclitaxel IV once weekly and trastuzumab IV once weekly for 12 weeks. Beginning 7 days after the completion of paclitaxel and trastuzumab, patients receive FEC comprising fluorouracil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Patients also receive trastuzumab IV once weekly for an additional 12 weeks. Within 6 weeks after completion of FEC and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab as in arm I. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies","id":"OG001","title":"Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75"}],"paramType":"NUMBER","populationDescription":"All patients that underwent breast surgery were included in this analysis.","reportingStatus":"POSTED","timeFrame":"From time surgery to up to 5 years","title":"Breast Conservation","type":"SECONDARY","unitOfMeasure":"percentage of participants"}